Baulac M - Search Results

1

Recent developments in treatment of status epilepticus: a review.

Rosenow F, Arzimanoglou A, Baulac M. Rosenow F, et al. Among authors: baulac m. Epileptic Disord. 2002 Oct;4 Suppl 2:S41-51. Epileptic Disord. 2002. PMID: 12424083 Free article. Review.

2

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.

Baulac M, Rosenow F, Toledo M, Terada K, Li T, De Backer M, Werhahn KJ, Brock M. Baulac M, et al. Lancet Neurol. 2017 Jan;16(1):43-54. doi: 10.1016/S1474-4422(16)30292-7. Epub 2016 Nov 24. Lancet Neurol. 2017. PMID: 27889312 Clinical Trial.

3

A common SCN1A splice-site polymorphism modifies the effect of carbamazepine on cortical excitability--a pharmacogenetic transcranial magnetic stimulation study.

Menzler K, Hermsen A, Balkenhol K, Duddek C, Bugiel H, Bauer S, Schorge S, Reif PS, Klein KM, Haag A, Oertel WH, Hamer HM, Knake S, Trucks H, Sander T, Rosenow F; EPICURE-Consortium. Menzler K, et al. Epilepsia. 2014 Feb;55(2):362-9. doi: 10.1111/epi.12515. Epub 2014 Jan 13. Epilepsia. 2014. PMID: 24417206 Free article. Clinical Trial.

4

[Therapeutic options provided by new antiepileptic drugs].

Baulac M, Arzimanoglou A, Semah F, Cavalcanti D. Baulac M, et al. Rev Neurol (Paris). 1997 Feb;153(1):21-33. Rev Neurol (Paris). 1997. PMID: 9296153 Review. French.

5

Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observational study. The French Gabapentin Collaborative Group.

Baulac M, Cavalcanti D, Semah F, Arzimanoglou A, Portal JJ. Baulac M, et al. Seizure. 1998 Feb;7(1):55-62. doi: 10.1016/s1059-1311(98)90009-7. Seizure. 1998. PMID: 9548227 Free article.

6

Is the underlying cause of epilepsy a major prognostic factor for recurrence?

Semah F, Picot MC, Adam C, Broglin D, Arzimanoglou A, Bazin B, Cavalcanti D, Baulac M. Semah F, et al. Among authors: baulac m. Neurology. 1998 Nov;51(5):1256-62. doi: 10.1212/wnl.51.5.1256. Neurology. 1998. PMID: 9818842

7

Rational conversion from antiepileptic polytherapy to monotherapy.

Baulac M. Baulac M. Epileptic Disord. 2003 Sep;5(3):125-32. Epileptic Disord. 2003. PMID: 14684346 Free article. Review.

8

De novo mutations in HCN1 cause early infantile epileptic encephalopathy.

Nava C, Dalle C, Rastetter A, Striano P, de Kovel CG, Nabbout R, Cancès C, Ville D, Brilstra EH, Gobbi G, Raffo E, Bouteiller D, Marie Y, Trouillard O, Robbiano A, Keren B, Agher D, Roze E, Lesage S, Nicolas A, Brice A, Baulac M, Vogt C, El Hajj N, Schneider E, Suls A, Weckhuysen S, Gormley P, Lehesjoki AE, De Jonghe P, Helbig I, Baulac S, Zara F, Koeleman BP; EuroEPINOMICS RES Consortium; Haaf T, LeGuern E, Depienne C. Nava C, et al. Among authors: baulac m, baulac s. Nat Genet. 2014 Jun;46(6):640-5. doi: 10.1038/ng.2952. Epub 2014 Apr 20. Nat Genet. 2014. PMID: 24747641

9

Parental mosaicism can cause recurrent transmission of SCN1A mutations associated with severe myoclonic epilepsy of infancy.

Depienne C, Arzimanoglou A, Trouillard O, Fedirko E, Baulac S, Saint-Martin C, Ruberg M, Dravet C, Nabbout R, Baulac M, Gourfinkel-An I, LeGuern E. Depienne C, et al. Among authors: baulac m, baulac s. Hum Mutat. 2006 Apr;27(4):389. doi: 10.1002/humu.9419. Hum Mutat. 2006. PMID: 16541393

10

Hippocampal developmental changes in patients with partial epilepsy: magnetic resonance imaging and clinical aspects.

Baulac M, De Grissac N, Hasboun D, Oppenheim C, Adam C, Arzimanoglou A, Semah F, Lehéricy S, Clémenceau S, Berger B. Baulac M, et al. Ann Neurol. 1998 Aug;44(2):223-33. doi: 10.1002/ana.410440213. Ann Neurol. 1998. PMID: 9708545 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

284 results

Search Page